Gene Information
Gene symbol: FANCA
Gene name: Fanconi anemia, complementation group A
HGNC ID: 3582
Synonyms: FAA, FA-H, FAH
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | ATM | 1 hits |
| 2 | BRCA1 | 1 hits |
| 3 | BRCA2 | 1 hits |
| 4 | DCLRE1A | 1 hits |
| 5 | ERCC1 | 1 hits |
| 6 | MSH2 | 1 hits |
| 7 | PALB2 | 1 hits |
| 8 | PARP1 | 1 hits |
| 9 | PDXP | 1 hits |
| 10 | RAD51 | 1 hits |
| 11 | RAD51C | 1 hits |
| 12 | RAD52 | 1 hits |
| 13 | TIPARP | 1 hits |
| 14 | TP53 | 1 hits |
| 15 | WRN | 1 hits |
| 16 | XPA | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 10919664 | The rationale underlying this hypothesis is derived from the clues provided by family breast cancer syndromes, in which susceptibility genes, including p53, ATM, BRCA1 and BRCA2, are involved within the common functional pathway of DSB-related checkpoint/ repair. |
| 2 | 10919664 | Support for our hypothesis comes from the observations that: (a) the extent of DSB-initiated CIN in tumors significantly increased as tumors progressed to poorer grades or later stages; (b) in the sequential steps toward CIN, the loci of p53 and ATM, the key checkpoint genes against DSB, were lost at the earliest stage; and (c) many loci identified to be important in breast tumorigenesis were the genomic sites possibly harboring the genes involved in DSB-related checkpoint/repair (including RAD51, RAD52, and BRCA1) or CIN (including FA-A, FA-D, and WRN), and a higher number of these loci showing LOH was significantly associated with increased level of DSB-initiated CIN (P < 0.0001). |
| 3 | 35293552 | The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1. |
| 4 | 35293552 | The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1. |
| 5 | 35293552 | The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively). |
| 6 | 35293552 | The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively). |
| 7 | 35293552 | The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98). |
| 8 | 35293552 | The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98). |
| 9 | 35293552 | The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients. |
| 10 | 35293552 | The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients. |